Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jul 12,2023
Five times in a row! Medicilon was shortlisted in the "2022 China CXO Enterprises Top 20 List"
On June 27, the 2022 China Pharmaceutical Industry Top 100 Series List was released. Shanghai Medicilon Inc. was once again shortlisted in the "China CXO Enterprises Top 20 List".
More
Five times in a row! Medicilon was shortlisted in the "2022 China CXO Enterprises Top 20 List"
Jul 12,2023
CRO joins with technical companies to promote the transformation of innovative drug research and development, Medicilon and SciMatchmaker reached a strategic collaboration
Recently, Shanghai Medicilon Inc. (Medicilon) and SciMatchmaker reached a strategic collaboration. The two parties have reached an agreement on collaboration in new drug research and development and resource sharing.
More
CRO joins with technical companies to promote the transformation of innovative drug research and development, Medicilon and SciMatchmaker reached a strategic collaboration
Jul 07,2023
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recognizes the importance of drug discovery as the cornerstone of new drug innovation. Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division.
More
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Jul 04,2023
Medicilon appeared at the 25th SAPA-NE Annual Conference
The 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.
More
Medicilon appeared at the 25th SAPA-NE Annual Conference
Jun 26,2023
Reelected for 4 consecutive years! Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"
On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released. Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List.
More
Reelected for 4 consecutive years! Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"
Jun 26,2023
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
MindRank's GLP-1RA small molecule oral drug has been successfully administered to the first subject in clinical phase I. Medicilon as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.
More
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
Jun 21,2023
Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Recently, the IND application of TollB-001 Tablets, a class 1.1 new drug for rheumatoid arthritis by Toll Biotech, has been officially approved by the FDA. Medicilon provided pharmaceutical research services, including raw materials and preparation, for TollB-001 tablets, which accelerated the research process.
More
Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Jun 21,2023
To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration
Recently, Shanghai Medicilon Inc. (Medicilon) and DP Technology Ltd. announced the signing of a strategic collaboration agreement. The two parties will work together to build an integrated AI platform for early drug discovery and evaluation based on AI4S.
More
To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration
Jun 21,2023
Medicilon was honored as "2023 Growth Potential Company"
Shanghai Medicilon Inc. (Medicilon) was awarded the "2023 Growth Potential Company" by virtue of its stable and excellent profitability, innovation ability, and competitive strength.
More
Medicilon was honored as "2023 Growth Potential Company"
Jun 14,2023
Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD
Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China. Medicilon provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process.
More
Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD
Jun 14,2023
Medicilon interview with Dr. Fei Zhang | Walking in the dark with a light, Raymon Pharma's new medicinal technology benefits eye health
Shanghai Medicilon Inc. (Medicilon) has the honor to interview Dr. Fei Zhang, the founder of Raymon Pharma, to share his unique insights in the field of ophthalmic drugs.
More
Medicilon interview with Dr. Fei Zhang | Walking in the dark with a light, Raymon Pharma's new medicinal technology benefits eye health
Jun 08,2023
Jingxin Pharmaceutical awarded the Medicilon DMPK team and the New Drug Registration Department the "Outstanding Contribution Team Award"
Jingxin awarded the Medicilon DMPK team and the New Drug Registration Department "Outstanding Contribution Team Award" and a letter of thanks.
More
Jingxin Pharmaceutical awarded the Medicilon DMPK team and the New Drug Registration Department the "Outstanding Contribution Team Award"
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->